Bright Minds Biosciences (DRUG) Registration Filing summary

Company overview and business model

• Biotechnology company focused on developing treatments for neurological and psychiatric disorders, including epilepsy and depression, using novel serotonergic agonists and a portfolio of new chemical entities targeting CNS conditions.

• Incorporated in British Columbia in 2019, with headquarters in Vancouver, Chicago, and New York.

• Recent developments include the appointment of a new Chief Medical Officer and expansion of the Scientific Advisory Board.

Financial performance and metrics

• As of August 22, 2025, 7,088,639 common shares outstanding, with a market value of $110,732,998 for shares held by non-affiliates at a Nasdaq closing price of $43.96.

• Net tangible book value as of June 30, 2025, was $37,411,380 or $5.28 per share; post-offering, as adjusted, would be $134,084,105.83 or $14.33 per share, with immediate dilution of $29.63 per share to new investors at the offering price.

• No guaranteed, unguaranteed, secured, or unsecured indebtedness as of August 22, 2025.

Use of proceeds and capital allocation

• Net proceeds intended for sales and marketing, capital expenditures, further product development, operational expenditures, and general corporate and administrative purposes.

• Management has broad discretion over the use of proceeds, which may vary based on business conditions and progress of product development.